NuCana Prices $7 Million Registered Direct Offering

Core Viewpoint - NuCana plc has announced a registered direct offering of 10,845,985 American Depository Shares (ADSs) to raise approximately $7 million for advancing its drug discovery and development programs and general corporate purposes [1]. Group 1: Offering Details - The offering consists of ADSs or pre-funded warrants, each accompanied by Series A and Series B warrants with initial exercise prices of $0.8068 and $1.61 respectively [1]. - The combined public offering price for each ADS and the accompanying warrants is set at $0.6454, with a similar price for pre-funded warrants [1]. - The closing of the offering is expected to occur on or about May 7, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The gross proceeds from the offering are intended to fund activities related to drug discovery and development, as well as general corporate purposes including working capital, capital expenditures, investments, and potential acquisitions [1]. Group 3: Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which aims to enhance the efficacy and safety of conventional chemotherapy agents [5]. - The company's pipeline includes NUC-7738, currently in Phase 2 trials for advanced solid tumors, and NUC-3373, being evaluated in a Phase 1b/2 study in combination with pembrolizumab and docetaxel for various cancers [5].